Clinical trials: Chronic Obstruct Airways Disease
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
- Trial name
- COPD (NCT02512510)
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 611 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® in patients with chronic obstructive lung disease (COLD).
- Trial name
- NCT02231320
- Testing
- Berodual® Respimat® - inhaler
- Volunteers
- 236 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Validation of Structured Light Plethysmography - Health and Disease
Validation of Structured Light Plethysmography (SLP) in patients with conditions such as Chronic Obstructive Pulmonary Disease (COPD) that effect breathing and in healthy participants.
- Trial name
- SLP-RespDis (NCT02626468)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pneumacare Ltd
Chronic Obstructive Pulmonary Disease
Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation
This study will assess preliminary parameters of safety and efficacy of a single dose of BCT197 in patients with a Chronic Obstructive Pulmonary Disease (COPD) exacerbation.
- Trial name
- NCT01332097
- Testing
- BCT197, Prednisone
- Where
- 6 sites in Bulgaria, Romania and 1 more
- Volunteers
- 183 people
- Sponsor
- Mereo BioPharma
Pulmonary Disease, Chronic Obstructive
EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)
A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe…
- Trial name
- EROS+CP (US) (NCT06742736)
- Testing
- BGF
- Where
- United States
- Volunteers
- 13,000 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the Respimat inhaler, once daily for four weeks in…
- Trial name
- NCT00696020
- Testing
- BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
- Where
- 37 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects
The primary objective is to assess the pharmacokinetics (PK) of roflumilast and its metabolite roflumilast N-oxide after single and repeated oral administrations of roflumilast 500 μg in healthy Chinese subjects.
- Trial name
- NCT01354782
- Testing
- Roflumilast
- Where
- China
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe
This Phase 1, single-center study will be conducted in an open-label, randomized, parallel design. Healthy male and female participants aged 18 to 65 years will receive a single dose of itepekimab subcutaneous (SC) administered…
- Trial name
- NCT06114238
- Testing
- Itepekimab AI, Itepekimab PFS
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a two parts study, a single ascending dose followed by 14-days repeat dosing. The single ascending dose part will assess two dose levels of GSK3923868 or placebo across two treatment periods 1 and 2 in a single cohort of…
- Trial name
- NCT05677347
- Testing
- GSK3923868
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days
The study drug which is an inhaled bronchodilator (lung airway relaxant)has been given to both healthy volunteers and to COPD patients before. This study will assess a new formulation of GSK573719.
- Trial name
- NCT00732472
- Testing
- GSK573719
- Where
- 7 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, COPD
Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
Researchers are looking for new ways to treat chronic obstructive pulmonary disease (COPD). COPD is a long-lasting swelling of the airways that makes it hard to breathe.
- Trial name
- NCT05270525
- Testing
- Ensifentrine, LABA/LAMA
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive, Asthma
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD and known poor MDI inhalation technique following inhalation of Berodual delivered via the…
- Trial name
- NCT00267917
- Testing
- Berodual Respimat, Berodual HFA-MDI
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive…
- Trial name
- ECLIPSE (NCT00292552)
- Testing
- Novel endpoint determination
- Where
- 44 sites in United States, Bulgaria and 10 more
- Volunteers
- 2,747 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Fecal Microbiota Transplantation
Metabonomics of COPD and Transplanting of Faecal Bacteria in the Treatment of Its Malnutrition
Oxidative stress can affect the balance of intestinal flora and intestinal structure of patients, resulting in intestinal flora disorder.
- Trial name
- NCT04861649
- Testing
- fecal microbiota transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Asclepius Meditec Inc.
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical study, which aims to evaluate the efficacy, safety, and PK characteristics of Ensifentrine 3 mg twice daily (BID) for 24 weeks…
- Trial name
- NCT05743075
- Testing
- Ensifentrine
- Where
- China
- Volunteers
- 526 people
- Sponsor
- Nuance Pharma (shanghai) Co., Ltd
Chronic Obstructive Pulmonary Disease, COPD
A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease
The primary objective of this study is to demonstrate the superiority of tiotropium hydrofluoroalkane (HFA) breath actuated inhaler (BAI) to placebo HFA BAI following repeated, once-daily dosing.
- Trial name
- NCT02203474
- Testing
- Tiotropium HFA BAI 5 mcg, Tiotropium 18 mcg Capsule
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase II study is to evaluate the pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination (FDC 400/12 μg via the Almirall Inhaler and formoterol 12 μg via the Foradil®…
- Trial name
- NCT01551888
- Testing
- Aclidinium/formoterol 400/12μg, Formoterol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers
This trial in healthy subjects will assess PUR118's effect on attenuating ozone induced airway inflammation. This trial will establish the tolerability of PUR118 in healthy normal volunteers.
- Trial name
- NCT01690949
- Testing
- PUR118
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
COPD (Chronic Obstructive Pulmonary Disease), Chronic Bronchitis
Repeat Treatment With Metered Cryospray in Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
This study is being conducted to determine the safety of repeat metered cryospray (MCS) treatment in patients with COPD with chronic bronchitis previously treated with MCS.
- Trial name
- MCSRETREAT (NCT07468617)
- Testing
- Metered cryospray (MCS)
- Volunteers
- 10 people
- Sponsor
- CSA Medical, Inc.
COPD
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Trial name
- NCT02536508
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg
- Where
- 64 sites in United States
- Volunteers
- 627 people
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.